Abstract
8550Background: Multimodality therapy is recommended in the management of clinical stage IIIA-N2 non-small cell lung cancer (NSCLC). However, the optimal combination and sequence of treatments and ...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
